Filing Information

Inventor(s)	Frederick Naftolin · Ahmed Fadiel-Metwaly ·
Assignee(s)	Yale University ·  View assignee updates
Correspondent	WOLF GREENFIELD & SACKS, P.C. ·
Application Number	US11658214
Filing date	07/27/2005
PCT 371 date	07/02/2009
Publication date	12/03/2009
Predicted expiration date	07/27/2025
U.S. Classifications	424/138.1  · 435/71  ·
International Classifications	A61K39395  · C12Q102  ·
Kind Code	A1
PCT Application Number	WO20PCTUS0526712 - 07/27/2005

Patent Family

Abstract

The methods and compositions of the invention provide new diagnostic markers for cancers (e.g., ovarian cancer, PPC, etc.) and other proliferative diseases or conditions such as psoriasis and endometriosis. The methods and compositions of the invention further provide new treatments for such proliferative diseases or conditions.

Independent Claims | See all claims (28)

1. 1. A method of inhibiting a proliferative condition in an individual, comprising administering to the individual an effective amount of a binding agent which binds an ERM family protein.
2. 4-6. (canceled)
3. 11-16. (canceled)
4. 18. (canceled)
5. 21. (canceled)
6. 22. A method of diagnosis of a proliferative condition in an individual, comprising determining the amount and/or concentration of an ERM family protein in a body fluid sample from an individual suspected of having or at risk of having the proliferative condition, wherein an amount and/or concentration of the ERM family protein significantly higher in the body fluid sample from the individual than in a normal or control sample is indicative of the existence of the proliferative condition in the individual.
7. 23. A method of monitoring in an individual the progress or recurrence of a proliferative condition, comprising determining the amount and/or concentration of an ERM family protein in a body fluid sample from an individual who has or had the proliferative condition, wherein an amount and/or concentration of the ERM family protein significantly higher in the body fluid sample from the individual than that in a normal or control sample is indicative of the progress or recurrence of the proliferative condition in the individual.
8. 24-25. (canceled)
9. 30. (canceled)
10. 36-58. (canceled)